Point72 Europe (London) LLP Legend Biotech Corp Transaction History
Point72 Europe (London) LLP
- $1.48 Billion
- Q3 2024
A detailed history of Point72 Europe (London) LLP transactions in Legend Biotech Corp stock. As of the latest transaction made, Point72 Europe (London) LLP holds 80,400 shares of LEGN stock, worth $3.29 Million. This represents 0.26% of its overall portfolio holdings.
Number of Shares
80,400
Previous 22,245
261.43%
Holding current value
$3.29 Million
Previous $985,000
297.66%
% of portfolio
0.26%
Previous 0.09%
Shares
2 transactions
Others Institutions Holding LEGN
# of Institutions
225Shares Held
74.3MCall Options Held
279KPut Options Held
350K-
Price T Rowe Associates Inc Baltimore, MD11.2MShares$457 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA7.51MShares$307 Million5.1% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.64MShares$272 Million7.41% of portfolio
-
Black Rock Inc. New York, NY5.72MShares$234 Million0.01% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.04MShares$206 Million1.16% of portfolio
About Legend Biotech Corp
- Ticker LEGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 167,403,008
- Market Cap $6.85B
- Description
- Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...